Lataa...
New targeted therapies in pancreatic cancer
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does not exceed 6 mo, likely due to natural resistance to gemcitabine. Therefore, it is hoped that more favorable results c...
Tallennettuna:
| Julkaisussa: | World J Gastroenterol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Baishideng Publishing Group Inc
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445091/ https://ncbi.nlm.nih.gov/pubmed/26034349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i20.6127 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|